Pulse Biosciences closed enrollment in its PRECISE-BTN study on September 15, 2026, and the same filing confirmed that the trial’s first enrolled patient has already completed a final follow-up visit. Both milestones arriving together matters because they compress the window to a primary dataset: with enrollment done and the follow-up clock already running on the earliest patients, the company moves toward readout without a gap between accrual and outcome.
The study evaluates the nPulse Vybrance Percutaneous Electrode System, which received FDA 510(k) clearance for soft-tissue ablation in March 2024, for symptomatic benign thyroid nodules. According to verified reporting, the trial expanded from an initial 50-patient target to 100 patients, and its endpoints span nodule volume reduction, symptom relief, and quality of life. The nodule-volume endpoint carries the most regulatory weight: a meaningful, durable reduction in a blinded measurement is the kind of evidence that supports broader clinical adoption of a non-surgical ablation approach.
The competitive context for that evidence has sharpened recently. STARMED America received FDA 510(k) clearance in May 2026 for a radiofrequency ablation device specifically indicated for benign thyroid nodules in adults, making it an active comparator in the minds of clinicians and payers even if it is not the trial’s control arm. Pulse’s nPulse technology uses nanosecond pulsed electric fields rather than thermal energy, a mechanistic difference the company argues reduces collateral tissue damage, but PRECISE-BTN’s data will need to show that distinction translates into a clinical outcome rather than a device-specification advantage.
The number to track now is nodule volume reduction at the primary timepoint. If the trial’s design calls for follow-up consistent with the first patient’s completion, a dataset is likely within reach in the next several months. That readout will determine whether Pulse can convert cleared-device status into actual procedural volume against an increasingly defined field of thyroid ablation alternatives.
Source link: https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/plse20260827_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
